JPRN-UMIN000012024已完成未知
Evaluation of long-acting insulin dose corresponding to lixisenatide dose in combination therapy of insulin and lixisenatide - Evaluation of long-acting insulin dose corresponding to lixisenatide dose
Kitano Hospital, The Tazuke Kofukai Medical Research Institute0 个研究点目标入组 40 人开始时间: 2013年10月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. The patients who did not agree with this study 2. The patients with serious complications 3. The patients who are at high risk for hypoglycemia 4. The patients who have the history of severe hypoglycemia (needed an emergency transport according to the hypoglycemia unawareness) 5. Those who are not approved to be eligible to this study by corresponding researcher or co-researchers
研究者
相似试验
招募中
1 期
A Phase I, open label study of extended dosing with PatrinTM in combination with temozolomide in the treatment of patients with advanced melanoma.Advanced melanomaCancer - Malignant melanomaACTRN12605000625673KuDOS Pharmaceuticals Limited132
尚未招募
不适用
Pharmacokinetic drug interaction between celecoxib and rebamipideKCT0000381Hanlim Pharmaceutical30
已完成
不适用
A dose finding study on the effect of continuous intake of test foods on the cognitive function. -a randomized, double-blind, parallel-group comparison trialHealthy adultsJPRN-UMIN000046397IMEQRD Co., Ltd60
进行中（未招募）
1 期
A research study to learn about the effects of IMB-1018972, to try and help your heart cell use energy more efficiently, to find the best dose, and to see how safe it is. This is for patients who may be at risk for a heart condition known as diabetic cardiomyopathy (DbCM) as a complication of a type 2 diabetes mellitus (T2DM).EUCTR2020-003280-26-GBImbria Pharmaceuticals, Inc.36
招募中
1 期
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s diseaseParkinson’s diseaseMedDRA version: 20.0Level: PTClassification code: 10061536Term: Parkinson's disease Class: 100000004852CTIS2022-500424-30-00409